Popular search terms:
Search Results
79 results found-
CSL Seqirus is Fully Prepared to Implement the WHO’s Trivalent Influenza Vaccines Strain Selection for the 2025/26 Canadian Influenza Season
https://www.cslseqirus.ca/news/canadian-audience-only -
CSL Seqirus, a business of CSL (ASX: CSL), today announced new data from five studies reinforcing the importance of seasonal influenza vaccination and exhibiting the benefits of cell-based influenza vaccines among people aged 6 months to 64 years.
https://www.cslseqirus.ca/news/idweek-2024 -
CSL Seqirus, a business of CSL (ASX: CSL), announced data from a range of real-world evidence (RWE) studies, highlighting the important role influenza vaccination plays in protecting public health.
https://www.cslseqirus.ca/news/options -
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.cslseqirus.ca/news -
CSL Seqirus is a global influenza vaccine company developing innovative solutions to ensure epidemic and pandemic preparedness throughout the world.
https://www.cslseqirus.ca/our-company -
CSL Seqirus, a business of CSL (ASX: CSL), has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to fill and finish additional pre-pandemic vaccine doses as part of the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS).
https://www.cslseqirus.ca/news/avian -
As is with other influenza vaccines, children who have received the appropriate course of FLUAD® Pediatric or another seasonal influenza vaccine are considered to be primed.
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-en/20240417approvede139338ctrl285766fluadpm-asu-20242025.pdf -
Therefore, inactivated influenza vaccines are standardized to contain the hemagglutinin of influenza virus strains representing the influenza viruses likely to circulate in Canada in the upcoming winter on the basis of the recommendations from the World Health Organization (WHO) and the National Advisory Committee on Immunization (NACI).
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-en/flucelvax-quad_en-clean-pm_asu-2024-2025_watermark.pdf -
FLUCELVAX® QUAD Influenza Vaccine (surface antigen, inactivated, prepared in cell cultures) Page 8 of 30 Percentages of Subjects with Any (Severe) Solicited Reactions3 18 to less than 65 years of age ≥ 65 years of age Trivalent Influenza Trivalent FLUCELVAX® FLUCELVAX® QUAD Vaccine Influenza Vaccine QUAD N=663 TIV1c TIV2c TIV1c TIV2c N=656 N=330 N=327 N=340 N=336 Fever:
https://www.cslseqirus.ca/-/media/seqirus-canada/docs-en/20240416_285764_flucelvax-quad_en-clean-pm_asu-2024-2025.pdf -
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.cslseqirus.ca/news/news-archives